|
|
Дата |
|---|
| 19:06 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
| 04.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
0.63
|
0.7041
|
0.5717
|
0.5717
|
0.642
|
0.642
|
|
|
1 171.59
|
15.00
|
|
0.54
|
0.68
|
0.6661
|
0.57
|
0.6661
|
0.57
|
|
|
22 995.17
|
106.00
|
|
0.65
|
0.74
|
0.9401
|
0.6899
|
0.9401
|
0.7001
|
|
|
41 500.92
|
222.00
|
|
0.89
|
0.98
|
0.9246
|
0.9185
|
0.93995
|
0.9288
|
|
|
2 035.57
|
24.00
|
|
0.8808
|
0.96
|
0.9353
|
0.91
|
0.94
|
0.94
|
|
|
3 332.23
|
42.00
|
|
0.8412
|
0.98
|
0.8999
|
0.8999
|
0.9325
|
0.9325
|
|
|
2 071.02
|
20.00
|
|
0.8003
|
0.9195
|
0.811
|
0.8105
|
0.89545
|
0.8875
|
|
|
1 809.93
|
24.00
|
|
0.8053
|
0.92
|
0.8245
|
0.81745
|
0.84
|
0.828
|
|
|
20 833.01
|
163.00
|
|
0.80
|
0.86
|
0.8862
|
0.8002
|
0.8896
|
0.8051
|
|
|
4 457.13
|
25.00
|
|
0.8605
|
0.9658
|
0.87995
|
0.8605
|
0.9047
|
0.889445
|
|
|
10 050.22
|
53.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть| 13.11.2026 |
|
| 13.11.2026 |
|
| 13.08.2026 |
|
| 13.08.2026 |
|
| 14.05.2026 |
|